This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Quality Systems (QSII) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.
Pacific Biosciences (PACB) to Sell 10 PacBio Sequel Systems
by Zacks Equity Research
Pacific Biosciences of California, Inc. (PACB), announced that it will sell 10 PacBio Sequel Systems to Novogene Bioinformatics Technology Company, Ltd.
Akers Biosciences (AKER) Closes Offering of 1.7M Shares
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) recently announced the closing of a public offering of 1.7 million common shares.
Intuitive Surgical (ISRG) Expects Strong Revenues in Q4
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) announced that it expects fourth-quarter 2016 revenues of approximately $757 million.
Fluidigm: Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
The market is not really happy with South San Francisco, CA-based Fluidigm Corporation's (FLDM) preliminary results for the fourth quarter and full-year 2016.
Ecolab (ECL) Acquires Abednego Environmental, Shares Gain
by Zacks Equity Research
In a bid to strengthen its water solution line of offerings, St. Paul, MN-based Ecolab Inc. (ECL) announced the acquisition of Abednego Environmental Services.
DexCom Looking Forward to Strong Revenues in Q4 and 2016
by Zacks Equity Research
DexCom, Inc. (DXCM), a renowned medical device company, reported that it expects preliminary, unaudited revenue of approximately $168 million for the fourth quarter ended Dec 31, 2016.
Teleflex Launches LMA Gastro Airway, FDA Okays Arrow VPS
by Zacks Equity Research
Teleflex Inc. (TFX) recently announced the launch of LMA Gastro Airway with Cuff Pilot Technology and the receipt of 510(k) approval from the U.S. FDA for its Arrow VPS Rhythm device.